NAD+ for Long COVID and ME/CFS: What the Evidence Shows

Few conditions are as exhausting — or as poorly served by medicine — as long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Crushing fatigue, post-exertional crashes, and brain fog can persist for months or years with no approved drug to fix them. Into that vacuum has stepped a confident wellness pitch: that "boosting your NAD+" — with intravenous drips, nicotinamide riboside (NR), or NMN — can restore the cellular energy these illnesses seem to drain. The biology sounds tailor-made for the problem.

But long COVID and ME/CFS are exactly the kind of high-burden, low-treatment conditions where desperate patients are most vulnerable to overselling. So this page lays out, honestly, why NAD+ is even a candidate, what the small human studies actually found (a little — and only in some people), and where the evidence stops well short of the marketing.

Why NAD+ is even a candidate here

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell that carries electrons through the reactions turning food into usable energy, and it also fuels DNA-repair enzymes and the sirtuins. Because it sits at the center of energy metabolism, low NAD+ availability can ripple outward into mitochondrial and metabolic dysfunction ¹ — and NAD+ tends to fall with age and metabolic stress in human tissue ². That makes "low cellular energy" diseases an intuitive target.

There is also a more specific, COVID-flavored rationale. The virus appears to disturb tryptophan metabolism — the same pathway the body uses to make NAD+ from scratch. Metabolomic studies of people recovering from COVID-19 found incomplete systemic recovery, including persistent disturbances in tryptophan and related metabolism weeks after the acute infection ³, and the kynurenine pathway (which both consumes tryptophan and feeds NAD+ synthesis) is measurably altered in COVID-19 ⁴. So the hypothesis isn't fringe: viral infection may bend the very pathway that supplies NAD+, and replenishing NAD+ might, in theory, help.

The trouble, as always with NAD+, is the distance between "plausible mechanism" and "proven treatment."

What the human studies actually found

The honest headline: the direct human evidence in long COVID is one small, uncontrolled pilot — and the ME/CFS evidence, while slightly better, is modest and mixed.

Long COVID. The most-cited study is a 2024 pilot that gave 36 people with persistent moderate-to-severe post-COVID fatigue a combination of low-dose naltrexone (LDN, 4.5 mg/day) plus NAD+ (delivered via patches) for 12 weeks ⁵. Fatigue scores improved meaningfully on the Chalder Fatigue Scale, quality of life rose, and about 52% of patients met "responder" criteria ⁵. That sounds encouraging — but read the design honestly: there was no placebo group and no randomization. With an illness that often improves on its own over months, and a treatment that bundled two interventions (LDN and NAD+) plus the attention of a clinical trial, there is no way to know how much of that benefit was the NAD+, the naltrexone, natural recovery, or placebo. The authors themselves framed it as "safe and may be beneficial in a subset" — a hypothesis, not a verdict.

ME/CFS. The somewhat stronger evidence comes from ME/CFS, where NAD+-adjacent supplements have actually been tested in randomized, placebo-controlled trials — though the NAD+ was given as NADH (the reduced form) paired with coenzyme Q10, not as an IV drip. A 207-person randomized double-blind trial of CoQ10 (200 mg) plus NADH (20 mg) daily for 12 weeks found a significant reduction in perceived cognitive fatigue and improved quality of life versus baseline ⁶, and an earlier randomized trial from the same group reported effects on heart-rate recovery after exercise ⁷. These are real, controlled signals — but they are modest, on subjective and physiological surrogate endpoints, and they test a CoQ10+NADH combination, so they can't be read as "NAD+ works for ME/CFS" on its own. A broader systematic review of randomized trials in CFS/ME underscores how small and heterogeneous this whole literature is, with no single intervention establishing itself as clearly effective ⁸.

It's also worth being precise about what LDN — the other half of that long COVID pilot — is and isn't. There's a genuine mechanistic line of research on low-dose naltrexone in ME/CFS via the TRPM3 ion channel on immune cells ⁹, which is part of why LDN keeps appearing in these protocols. But that's preclinical and exploratory pharmacology, not proof that the LDN-plus-NAD+ combo treats long COVID. The mechanism is interesting; the outcome data are thin.

Why "raises NAD+" still isn't "fixes fatigue"

Even setting long COVID aside, the wider NAD+ literature is a cautionary tale about exactly this leap. The credible clinical trials on raising NAD+ use oral precursors (NMN and NR), and they reliably move the biomarker — but converting that into felt benefit has been disappointing. When nicotinamide riboside raised blood NAD+ in older adults with mild cognitive impairment, neurocognitive scores were unchanged ¹⁰. A systematic review and meta-analysis of NAD+ precursors on metabolic-syndrome parameters found clinical benefits limited and inconsistent despite reliably raised NAD+ ¹¹. If precursors with real trials struggle to turn higher NAD+ into measurable improvements in healthier populations, that's a strong reason for caution before assuming an IV drip will resolve the profound fatigue of long COVID or ME/CFS. We walk through this "biomarker is not benefit" problem in depth in our pillar guide to NAD+ therapy evidence and in does NAD+ actually boost energy.

And the IV route specifically — the most heavily marketed and most expensive option — has no long COVID or ME/CFS outcome trials at all. The single human IV NAD+ study ever published measured only the metabolome of a 6-hour infusion and found free NAD+ wasn't even readily detectable in blood for hours ¹²; it tested no clinical outcome. We cover that route in detail in NAD+ IV therapy evidence and cost.

An honest bottom line for patients

Where does that leave someone living with long COVID or ME/CFS?

• •The mechanism is genuinely plausible — COVID disturbs the tryptophan/NAD+ pathway ³⁴, and these illnesses look like "low cellular energy" states ¹.
• •The direct human evidence is early and weak: one uncontrolled long COVID pilot (LDN + NAD+) ⁵, and modest randomized signals for CoQ10+NADH in ME/CFS ⁶⁷ within a small, mixed literature ⁸.
• •The benefit, where seen, appears in a subset of patients, at the group level it's limited, and none of it is proven in the way an approved therapy would be.
• •The IV route has no outcome trials, and NAD+ precursors broadly raise the biomarker without reliably improving how people feel ¹⁰¹¹.

That doesn't make NAD+ worthless to explore — it makes it an unproven, early-stage option, best discussed with a physician who manages your condition, not a shortcut to buy from a drip clinic. Be especially wary of any clinic presenting NAD+ as a "fix" for long COVID or ME/CFS: the honest framing is "promising mechanism, weak and preliminary evidence, helps some people in uncontrolled reports." If you're weighing it, understand the whole picture first — start with our NAD+ therapy evidence pillar, see the route reality in NAD+ IV therapy evidence, review the side effects before any drip, and see how products and providers compare on our NAD+ rankings hub.